Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5NIH 4OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 48Gastrointestinal 8CNS 6Tumor-Agnostic 2Thoracic 2Head & Neck 1Gynecologic 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × trastuzumab deruxtecan × Tumor-Agnostic × Clear all
NCT07086768 2026-06-03

Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 1 Recruiting
57 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07126561 2026-01-08

Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers

University of Chicago

Phase 2 Not yet recruiting
43 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡